SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VGNX -- Variagenics, Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (7)4/27/2001 10:20:05 AM
From: scaram(o)uche  Read Replies (1) of 269
 
This, in my opinion, could be a sleeper patent. It's the reason, in context of the remaining programs at VGNX, that I was amazed to see this cap drop to cash.

I don't have the background re. large deletions in cancer to comment in depth. As SI biofreaks find the time, it may well be worth gathering the background.

Could be a huge patent. Or, could be wishful thinking, based on my relative ignorance of "loss of SNP-detected, drug-selectable" markers. On paper, this sounds like the perfect approach to using potent tumor-specific poisons in humans.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News